# Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation

> **NCT00993343** · PHASE3 · COMPLETED · sponsor: **Karolinska Institutet** · enrollment: 215 (actual)

## Conditions studied

- Graft-versus-host Disease
- Survival

## Interventions

- **DRUG:** Sirolimus/tacrolimus
- **DRUG:** cyclosporine/methotrexate

## Key facts

- **NCT ID:** NCT00993343
- **Lead sponsor:** Karolinska Institutet
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-04
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00993343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00993343, "Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00993343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*